NeoPharm enrolls patients

LAKE BLUFF - NeoPharm Inc. announced that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel, as a front-line treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere. "Unfortunately, pancreatic cancer is one of the cancers which has no effective treatment. We are hoping that this new modality of treatment with LE-DT will bring some hope and treatment options to those unfortunate patients" said Dr. Aquilur Rahman, president and CEO of NeoPharm.